Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O60869
UPID:
EDF1_HUMAN
Alternative names:
Multiprotein-bridging factor 1
Alternative UPACC:
O60869; Q5T5T2; Q9UIM1
Background:
Endothelial differentiation-related factor 1, also known as Multiprotein-bridging factor 1, plays a pivotal role in various biological processes. It acts as a transcriptional coactivator, enhancing the activities of NR5A1, NR1H3/LXRA, PPARG, ATF1, ATF2, and CREB1. Additionally, it regulates nitric oxide synthase activity by modulating calmodulin sequestration in the cytoplasm, and is involved in endothelial cells differentiation, hormone-induced cardiomyocytes hypertrophy, and lipid metabolism.
Therapeutic significance:
Understanding the role of Endothelial differentiation-related factor 1 could open doors to potential therapeutic strategies.